Please login to the form below

Not currently logged in
Email:
Password:

Denali Therapeutics

This page shows the latest Denali Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Also working within the RIPK1 inhibitor space is Sanofi and Denali Therapeutics. ... In 2018, Sanofi paid Denali $125m upfront for access to two of the company’s RIPK1 inhibitors.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Faced with that litany of failures, researchers are branching out beyond old approaches to amyloid- beta (Abeta) in search of effective therapeutics. ... Denali Therapeutics is collaborating with Sanofi on a drug designed to alleviate inflammatory

  • Deal Watch January 2018

    th. in the top deal makers of 2017, had a busy first week of the New Year, entering into an option and collaboration agreement with Denali Therapeutics paying $155m on agreement ... Acquisition company. 4, 800. Denali Therapeutics/ Takeda Pharmaceutical.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....